Endocrinol Metab.  2020 Jun;35(2):237-242. 10.3803/EnM.2020.35.2.237.

Epidemiology of Functioning Pituitary Adenomas

• Chin SO

• KMID: 2503254
• DOI: http://doi.org/10.3803/EnM.2020.35.2.237

Abstract

Pituitary adenomas (PAs) are defined as benign monoclonal tumors in the pituitary gland that cause symptoms due to either hormonal hypersecretion or a space-occupying effect, and are classified as functioning or non-functioning. Because of their rarity and slow-growing with symptomless nature in most cases, it has been challenging to investigate the epidemiology of PAs. Considering their public health impact and association with increased morbidity and mortality, however, it is essential to understand the prevalence and incidence of PAs in order to improve patient outcomes and to minimize the resultant burden on the health care system. Fortunately, developments in imaging modalities and easier access to large-scale population data have enabled investigators to analyze the epidemiology of PAs more accurately. This review summarizes previously reported epidemiologic data on functioning PAs in Korea and other countries.

Keyword

Pituitary neoplasms; Epidemiology; Korea

Reference

1. Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol. 2014; 117:379–94.

2. Sivakumar W, Chamoun R, Nguyen V, Couldwell WT. Incidental pituitary adenomas. Neurosurg Focus. 2011; 31:E18.

3. Cho HJ, Kim H, Kwak YJ, Seo JW, Paek SH, Sohn CH, et al. Clinicopathologic analysis of pituitary adenoma: a single institute experience. J Korean Med Sci. 2014; 29:405–10.

4. Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. 2014; 170:R121–32.

5. Buchfelder M, Schlaffer S. Imaging of pituitary pathology. Handb Clin Neurol. 2014; 124:151–66.

6. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer. 2001; 8:287–305.

7. Krysiak R, Okopien B, Korzekwa M. Atypical pituitary tumors. Pol Merkur Lekarski. 2012; 32:323–8.

8. Chanson P, Brochier S. Non-functioning pituitary adenomas. J Endocrinol Invest. 2005; 28:93–9.

9. Fleseriu M, Bodach ME, Tumialan LM, Bonert V, Oyesiku NM, Patil CG, et al. Congress of neurological surgeons systematic review and evidence-based guideline for pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery. 2016; 79:E527–9.

10. Laws ER Jr, Penn DL, Repetti CS. Advances and controversies in the classification and grading of pituitary tumors. J Endocrinol Invest. 2019; 42:129–35.

11. Hemminki K, Forsti A, Ji J. Incidence and familial risks in pituitary adenoma and associated tumors. Endocr Relat Cancer. 2007; 14:103–9.

12. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001; 3:152–8.

13. Park KH, Lee EJ, Seo GH, Ku CR. Risk for acromegaly-related comorbidities by sex in Korean acromegaly. J Clin Endocrinol Metab. 2020; 105:dgz317.

14. Park KH, Choi JG, Tae ES, Song SO, Nam JY, Song YD. Rare intractable pituitary diseases: analysis on their epidemiology and use of benefit extension policy (No. 2015-20-025). Goyang: National Health Insurance Service Ilsan Hospital;2015.

15. Seo GH, Choe EK, Park KJ, Chai YJ. Incidence of adhesive bowel obstruction after colon cancer surgery and its risk factors: a nationwide claim study. Ann Surg. 2018; 268:114–9.

16. Yun JM, Shin DW, Hwang SS, Cho J, Nam YS, Kim JH, et al. Effect of public disclosure on antibiotic prescription rate for upper respiratory tract infections. JAMA Intern Med. 2015; 175:445–7.

17. Seong SC, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol. 2017; 46:799–800.

18. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009; 119:3189–202.

19. Melmed S, Ezrin C, Kovacs K, Goodman RS, Frohman LA. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med. 1985; 312:9–17.

20. Beuschlein F, Strasburger CJ, Siegerstetter V, Moradpour D, Lichter P, Bidlingmaier M, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med. 2000; 342:1871–6.

21. Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, et al. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982; 70:965–77.

22. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010; 72:377–82.

23. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006; 91:4769–75.

24. Tjornstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosen T, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocrinol. 2014; 171:519–26.

25. Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol. 2015; 173:655–64.

26. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary. 2015; 18:803–7.

27. Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab. 2010; 95:4268–75.

28. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016; 175:181–90.

29. Bex M, Abs R, T’Sjoen G, Mockel J, Velkeniers B, Muermans K, et al. AcroBel–the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007; 157:399–409.

30. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004; 151:439–46.

31. Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013; 16:545–53.

32. Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016; 19:262–7.

33. Caputo M, Ucciero A, Mele C, De Marchi L, Magnani C, Cena T, et al. Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy. J Endocrinol Invest. 2019; 42:397–402.

34. Sader MA, McGrath KC, Hill MD, Bradstock KF, Jimenez M, Handelsman DJ, et al. Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis. Clin Endocrinol (Oxf). 2005; 62:56–63.

35. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988; 223:327–35.

36. Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J. 1990; 59:55–62.

37. Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993; 16:181–7.

38. Lee SJ, Chai ES, Chough CB, Kim CH, Choi HJ. Case report: two cases of active acromegaly. Korean J Med. 1965; 8:241–7.

39. Yang IM. Clinical characteristics of acromegalic patients in Korea. J Korean Soc Endocrinol. 1994; 9:290–306.

40. Kwon O, Song YD, Kim SY, Lee EJ, et al. Rare Disease Study Group; Science and Research Committee. Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf). 2013; 78:577–85.

41. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:273–88.

42. Vroonen L, Daly AF, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019; 109:20–7.

43. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004; 101:613–9.

44. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003; 148:325–31.

45. Cushing H. The pituitary body and its disorders: clinical states produced by disorders of the hypophysis cerebri. Philadelphia: JB Lippincott;1912.

46. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4:611–29.

47. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994; 40:479–84.

48. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86:117–23.

49. The Korean Society of Endocrinology; The Survey Committee for Endocrine Disease in Korea. The incidence and clinical characteristics of Cushing’s syndrome in Korea. J Korean Soc Endocrinol. 2000; 15:31–45.

50. Jailer JW, Holub DA. Remission of Graves’ disease following radiotherapy of a pituitary neoplasm. Am J Med. 1960; 28:497–500.

51. Amlashi FG, Tritos NA. Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine. 2016; 52:427–40.

52. Azzalin A, Appin CL, Schniederjan MJ, Constantin T, Ritchie JC, Veledar E, et al. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary. 2016; 19:183–93.

53. Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg. 2014; 121:1462–73.

54. Yoon HJ, Hong DS, Hong KS, Cha BY, Kim YW, Son HY. A case of TSH secreting pituitary tumor. J Korean Soc Endocrinol. 1986; 1:55–62.

55. Lee WK, Hwang S, Lim JS, Kim HM, Lee EY, Lee SK, et al. Clinical and biochemical characteristics and treatment of patients with thyrotropin-secreting pituitary adenomas. Korean J Med. 2011; 80:47–55.

56. Onnestam L, Berinder K, Burman P, Dahlqvist P, Engstrom BE, Wahlberg J, et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab. 2013; 98:626–35.

57. Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013; 2:76–82.